Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mission Therapeutics appoints Colin Goddard to board

This article was originally published in Scrip

Executive Summary

Mission Therapeutics, a drug discovery and development company, has named Dr Colin Goddard, former CEO of OSI Pharmaceuticals, to its board of directors. Dr Goddard joined OSI as a research scientist in 1989 and led the transformation of the technology platform services company into a profitable fully integrated biopharmaceutical organization, becoming CEO in 1998. OSI was acquired by Astellas Pharma in June 2010 for $4bn.

Related Companies

UsernamePublicRestriction

Register

SC029241

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel